GanoMycin I

Modify Date: 2024-01-02 08:29:50

GanoMycin I structure	Common Name	GanoMycin I
	CAS Number	1191255-15-8	Molecular Weight	342.43
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₁H₂₆O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of GanoMycin I

Ganomycin I is a dual inhibitor of α-Glucosidase and HMG-CoA reductase. Ganomycin I can also inhibits HIV protease. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects[1][2].

Name	(R)-ganomycin I

Description	Ganomycin I is a dual inhibitor of α-Glucosidase and HMG-CoA reductase. Ganomycin I can also inhibits HIV protease. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HMG-CoA Reductase (HMGCR) Research Areas >> Infection Research Areas >> Metabolic Disease Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease
References	[1]. Tran PT, et, al. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1. Phytomedicine. 2019 Mar 1;55:1-8. [2]. Wang K, et, al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. J Med Chem. 2018 Apr 26;61(8):3609-3625.

Description

Ganomycin I is a dual inhibitor of α-Glucosidase and HMG-CoA reductase. Ganomycin I can also inhibits HIV protease. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects[1][2].

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> HMG-CoA Reductase (HMGCR)

Research Areas >> Infection

Research Areas >> Metabolic Disease

Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease

References

[1]. Tran PT, et, al. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1. Phytomedicine. 2019 Mar 1;55:1-8.

[2]. Wang K, et, al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. J Med Chem. 2018 Apr 26;61(8):3609-3625.